Compare WHR & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHR | HCM |
|---|---|---|
| Founded | 1911 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 1994 | N/A |
| Metric | WHR | HCM |
|---|---|---|
| Price | $40.47 | $11.10 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 9 | 1 |
| Target Price | ★ $74.33 | $13.75 |
| AVG Volume (30 Days) | ★ 2.5M | 47.8K |
| Earning Date | 05-06-2026 | 03-05-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | ★ 196.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,253,000,000.00 | N/A |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | $3.48 | $15.62 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | ★ 2.58 | N/A |
| 52 Week Low | $36.01 | $9.77 |
| 52 Week High | $107.93 | $19.50 |
| Indicator | WHR | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 50.38 |
| Support Level | $38.51 | $9.77 |
| Resistance Level | $45.07 | $15.59 |
| Average True Range (ATR) | 2.25 | 0.31 |
| MACD | 0.40 | 0.15 |
| Stochastic Oscillator | 80.51 | 64.71 |
Whirlpool Corp is a manufacturer and marketer of kitchen and laundry appliances, with its presence in different markets around the world. It offers products like refrigerators, washing machines, cooktops, ovens, freezers, and others, which are marketed through various brands such as KitchenAid, Maytag, Amana, Brastemp, Consul, Whirlpool, Jennair, etc. The company's operating and reportable segments are: Major Domestic Appliances (MDA) North America (its key revenue-generating segment), MDA Europe, MDA Latin America, and Small Domestic Appliances (SDA) Global.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.